In one such study, 52% of thyroid tumor specimens carried clinically relevant mutations in at least one screened gene, most frequently involving KRAS (86%), followed by NRAS (7%), BRAF (6%), and combined NRAS + BRAF mutations (2%) [15]. The gene discussed is KRAS; the disease is thyroid tumor.